X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
PP&E Gross
ÂĄ541.9m
CAGR 3-Years
56%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
PP&E Gross
ÂĄ9.3B
CAGR 3-Years
54%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
PP&E Gross
ÂĄ2.9B
CAGR 3-Years
46%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
PP&E Gross
ÂĄ1.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
PP&E Gross
ÂĄ5.1B
CAGR 3-Years
20%
CAGR 5-Years
25%
CAGR 10-Years
24%
Imeik Technology Development Co Ltd
SZSE:300896
PP&E Gross
ÂĄ300.4m
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's PP&E Gross?
PP&E Gross
541.9m CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's PP&E Gross amounts to 541.9m CNY.

What is Xiamen Amoytop Biotech Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
48%

Over the last year, the PP&E Gross growth was 33%. The average annual PP&E Gross growth rates for Xiamen Amoytop Biotech Co Ltd have been 56% over the past three years , 48% over the past five years .

Back to Top